August 7, 2024

Company name: ROHTO Pharmaceutical Co., Ltd.
Representative: Masashi Sugimoto, President and COO
(Code: 4527 TSE Prime )
Contact: Masaya Saito, Vice President and CFO
(TEL: 06-6758-8223)

# Notice of Revision of Earnings Forecast and Dividend Forecast (Dividend Increase)

ROHTO PHARMACEUTICAL CO., LTD. (the "Company") hereby announces that, in light of the recent trends in business performance, the Company has revised its consolidated earnings forecast announced on May 13, 2024, as described below. The year-end dividend forecast has been revised.
The forecast indicated below is also disclosed in the "Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2025 (Three Months Ended June 30, 2024) [Japanese GAAP]."

1. Revisions to the earnings forecast

(1) Details of the revisions

Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2025 (April 1, 2024 to March 31, 2025)

| | Net sales | Operating profit | Ordinary profit | Profit attributable to owners of parent | Basic earnings per share |
|---|---|---|---|---|---|
| | Millions of yen | Millions of yen | Millions of yen | Millions of yen | Yen |
| Previous forecast (A) (Announced on May 13, 2024) | 300,000 | 43,000 | 44,000 | 32,000 | 140.27 |
| Revised forecast (B) | 320,000 | 43,200 | 44,200 | 32,200 | 141.14 |
| Change (B-A) | 20,000 | 200 | 200 | 200 | |
| Percentage change (%) | 6.7 | 0.5 | 0.5 | 0.6 | |
| (Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2024) | 270,840 | 40,048 | 42,434 | 30,936 | 135.61 |

(2) Reasons for the revisions

The Company has revised the consolidated financial earnings forecast announced on May 13, 2024 to reflect the earnings of Eu Yan Sang International Ltd. and Mono chem-pharm Produkte GmbH, whose shares the Company has acquired as was announced in the first quarter, in the consolidated earnings forecast from the third quarter onwards. Net sales, operating profit, ordinary profit, and profit attributable to owners of parent are all expected to exceed the previous forecast, resulting in increased sales and profits. The expected exchange rates remain unchanged at 148 yen to the US dollar and 20 yen to the Chinese yuan.

Revision of Year-end Dividend Forecast.

(3) Details of the revisions

Revision of dividend forecast for the fiscal Year Ending March 31, 2025 (April 1, 2024 to March 31, 2025)

| | Annual dividends(yen) | | |
|---|---|---|---|
| | 2nd quarter-end | Year-end | Total |
| Previous forecast (Announced on May 13, 2024) | 15.00 | 15.00 | 30.00 |
| Revised forecast | 16.00 | 17.00 | 33.00 |
| (Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2024) | 12.00 | 15.00 | 27.00 |

The Company executed a 2-for-1 stock split of shares of common stock on January 1, 2023.

(4) Reasons for the revisions

Consistently and continually returning to shareholders the profits earned through business activities is one of our highest priorities. The fundamental policy is to pay a dividend based on results of operations. Based on the earnings forecast for the fiscal year ending March 31, 2025 (April 1, 2024 to March 31, 2025), to enhance the return of profits to shareholders, for said fiscal year, the Company has decided to increase the dividend for the end of the second quarter by 1 yen to 16 yen per share, and the year-end dividend by 2 yen to 17 yen per share. As such, the total annual dividend will be 33 yen per share.

*The above earnings forecasts are based on information available as of the date of announcement. Final financial results may differ from the forecasts due to various factors.